Reduced Chemotherapy in Low Risk DLBCL
This is a clinical trial to compare the efficacy and safety of four cycles of R-CHOP followed by four cycles of Rituximab with six cycles of R-CHOP followed by two cycles of Rituximab in the treatment of de novo, low-risk, non-bulky diffuse large B-cell lymphoma.
Diffuse Large B-cell Lymphoma
DRUG: Rituximab|DRUG: Cyclophosphamide|DRUG: Epirubicin|DRUG: Vincristine|DRUG: Prednisone
Progression free survival, 2-year
Overall survival, 2-year|Complete Response rate, 21 days after 8 cycles of treatment（each cycle is 21 days）|Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0, Each cycle of treatment（each cycle is 21 days）and then every 3 months for 2 years
This is a clinical trial to compare the efficacy and safety of four cycles of R-CHOP followed by four cycles of Rituximab with six cycles of R-CHOP followed by two cycles of Rituximab in the treatment of de novo, low-risk, non-bulky diffuse large B-cell lymphoma.